EphA2-targeted immunoliposomes for delivering docetaxel are useful in the treatment of certain types of cancer. The immunoliposomes can include an EphA2 targeting moiety (e.g., a scFv) and encapsulate a docetaxel prodrug in a stable salt form within a liposome having an average size of about 100 nm. Novel docetaxel prodrugs suitable for loading into nanoliposomes (including immunoliposomes) are provided, along with novel and other useful EphA2 targeting moieties for preparation of EphA2-targeted doxorubicin-generating immunoliposome therapies. Pharmaceutical compositions can be prepared that include nanoliposomes encapsulating one or more docetaxel prodrugs, and/or immunoliposomes or nanoparticles comprising an EphA2 binding moiety and encapsulating one or more docetaxel prodrugs. The pharmaceutical compositions are useful for administration to a patient for the treatment of cancer.用於投遞歐洲紫杉醇之EphA2靶向性免疫微脂體係可用於治療某些類型癌症。該免疫微脂體可包括EphA2靶向部分(例如scFv)及囊封歐洲紫杉醇前藥於安定鹽類形式於微脂體內,該微脂體具有平均尺寸約100nm。所提供者係適用於裝載於奈米微脂體(包括免疫微脂體)中之新穎歐洲紫杉醇前藥,加上新穎及其他可用之EphA2靶向部分以供製備EphA2靶向性杜薩魯比辛(doxorubicin)產生免疫微脂體療法之用。醫藥組成物可予製備,其包括囊封一或多種歐洲紫杉醇前藥之奈米微脂體,和/或包含EphA2結合部分且囊封一或多種歐洲紫杉醇前藥之免疫微脂體或奈米粒子。該醫藥組成物係可用於投予患者以供治療癌之用。
